Astellas Makes U.S.-Based OSI Wholly Owned Subsidiary
This article was originally published in PharmAsia News
Executive Summary
Astellas Pharma formally announced it had completed its $4 billion buyout of U.S.-based OSI Pharmaceuticals, giving the Japanese drug maker greater presence in the oncology drug market